Capital Investment Advisory Services LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 1.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 8,422 shares of the company’s stock after acquiring an additional 99 shares during the quarter. Capital Investment Advisory Services LLC’s holdings in Johnson & Johnson were worth $1,114,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. OLD Point Trust & Financial Services N A grew its stake in Johnson & Johnson by 2.2% during the 2nd quarter. OLD Point Trust & Financial Services N A now owns 61,326 shares of the company’s stock worth $8,113,000 after buying an additional 1,321 shares during the last quarter. Lynch & Associates IN grew its stake in Johnson & Johnson by 0.9% during the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock worth $12,397,000 after buying an additional 841 shares during the last quarter. Oakbrook Investments LLC grew its stake in Johnson & Johnson by 7.4% during the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock worth $18,008,000 after buying an additional 9,375 shares during the last quarter. Trexquant Investment LP purchased a new position in Johnson & Johnson during the 1st quarter worth approximately $1,731,000. Finally, Janney Montgomery Scott LLC grew its stake in Johnson & Johnson by 0.5% during the 2nd quarter. Janney Montgomery Scott LLC now owns 771,868 shares of the company’s stock worth $102,110,000 after buying an additional 3,533 shares during the last quarter. Institutional investors and hedge funds own 65.93% of the company’s stock.
Johnson & Johnson (NYSE JNJ) opened at $139.56 on Monday. The stock has a market capitalization of $374,930.72, a price-to-earnings ratio of 19.55, a P/E/G ratio of 2.84 and a beta of 0.82. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.68 earnings per share. analysts predict that Johnson & Johnson will post 7.28 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.41%. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/13/johnson-johnson-jnj-stake-lifted-by-capital-investment-advisory-services-llc.html.
A number of research firms recently issued reports on JNJ. J P Morgan Chase & Co raised their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Jefferies Group LLC set a $145.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research report on Tuesday, August 15th. Citigroup Inc. initiated coverage on Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective for the company. BMO Capital Markets reaffirmed a “positive” rating and set a $152.00 price objective (up from $145.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. Finally, Royal Bank Of Canada increased their price objective on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $143.70.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.